2,166 Shares in Abbott Laboratories (NYSE:ABT) Bought by Good Steward Wealth Advisors LLC

Good Steward Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,166 shares of the healthcare product maker's stock, valued at approximately $287,000.

Other large investors also recently modified their holdings of the company. ORG Partners LLC boosted its position in Abbott Laboratories by 41.6% during the first quarter. ORG Partners LLC now owns 3,078 shares of the healthcare product maker's stock valued at $408,000 after purchasing an additional 904 shares during the last quarter. Investment Research & Advisory Group Inc. raised its stake in shares of Abbott Laboratories by 13.5% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 1,008 shares of the healthcare product maker's stock worth $134,000 after purchasing an additional 120 shares in the last quarter. River Street Advisors LLC boosted its holdings in shares of Abbott Laboratories by 13.9% in the 1st quarter. River Street Advisors LLC now owns 8,393 shares of the healthcare product maker's stock valued at $1,113,000 after buying an additional 1,023 shares during the last quarter. Walter & Keenan Wealth Management LLC IN ADV grew its stake in shares of Abbott Laboratories by 3.6% in the first quarter. Walter & Keenan Wealth Management LLC IN ADV now owns 10,010 shares of the healthcare product maker's stock valued at $1,328,000 after buying an additional 345 shares in the last quarter. Finally, Roberts Wealth Advisors LLC acquired a new position in Abbott Laboratories during the first quarter worth $223,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of the stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the sale, the director now directly owns 34,058 shares in the company, valued at $4,415,960.28. This represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $132.35 on Friday. The company has a quick ratio of 1.27, a current ratio of 1.78 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $230.27 billion, a price-to-earnings ratio of 17.17, a price-to-earnings-growth ratio of 2.51 and a beta of 0.73. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23. The company has a 50-day simple moving average of $132.07 and a two-hundred day simple moving average of $126.76.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating analysts' consensus estimates of $1.07 by $0.02. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. Abbott Laboratories had a net margin of 31.89% and a return on equity of 19.01%. Analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a dividend yield of 1.78%. The ex-dividend date is Tuesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 30.61%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ABT shares. Leerink Partnrs raised shares of Abbott Laboratories to a "hold" rating in a research report on Monday. Barclays boosted their price target on Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a research report on Thursday, April 17th. Bank of America raised their price objective on Abbott Laboratories from $133.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Leerink Partners started coverage on Abbott Laboratories in a report on Monday. They set a "market perform" rating and a $143.00 target price on the stock. Finally, Jefferies Financial Group raised their price target on Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a report on Thursday, April 17th. Six analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $142.61.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.